BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25436731)

  • 41. 11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
    Koh EH; Kim AR; Kim H; Kim JH; Park HS; Ko MS; Kim MO; Kim HJ; Kim BJ; Yoo HJ; Kim SJ; Oh JS; Woo CY; Jang JE; Leem J; Cho MH; Lee KU
    J Endocrinol; 2015 Jun; 225(3):147-58. PubMed ID: 25869616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
    Hong SP; Han D; Chang KH; Ahn SK
    Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preadipocyte 11beta-hydroxysteroid dehydrogenase type 1 is a keto-reductase and contributes to diet-induced visceral obesity in vivo.
    De Sousa Peixoto RA; Turban S; Battle JH; Chapman KE; Seckl JR; Morton NM
    Endocrinology; 2008 Apr; 149(4):1861-8. PubMed ID: 18174284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 11beta-hydroxysteroid dehydrogenase type 1 of the subcutaneous adipose tissue is dysregulated but not associated with metabolic disorders in adults born small for gestational age.
    Meas T; Carreira E; Wang Y; Rauh M; Poitou C; Clément K; Dötsch J; Lévy-Marchal C
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3949-54. PubMed ID: 20519348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
    Morris DJ; Latif SA; Hardy MP; Brem AS
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.
    Diederich S; Quinkler M; Mai K; Schöneshöfer M; Baehr V; Pfeiffer A; Oelkers W; Eigendorff E
    Horm Metab Res; 2011 Jan; 43(1):66-71. PubMed ID: 20925019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of 11β-HSD1 expression during adipose tissue expansion by hypoxia through different activities of NF-κB and HIF-1α.
    Lee JH; Gao Z; Ye J
    Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1035-41. PubMed ID: 23512810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
    Rask E; Walker BR; Söderberg S; Livingstone DE; Eliasson M; Johnson O; Andrew R; Olsson T
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
    Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
    Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM; Hachey DL; Hasty AH
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
    Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
    Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
    J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.
    Candia R; Riquelme A; Baudrand R; Carvajal CA; Morales M; Solís N; Pizarro M; Escalona A; Carrasco G; Boza C; Pérez G; Padilla O; Cerda J; Fardella CE; Arrese M
    Liver Int; 2012 Mar; 32(3):392-9. PubMed ID: 22136330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
    Walker BR; Andrew R
    Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
    Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
    Seckl JR; Walker BR
    Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
    Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
    Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.